CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 482052-482485 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T64882","span":{"begin":0,"end":433},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Medication compliance is recognized as a significant challenge in pediatrics.The purpose of this study was to compare inhaled corticosteroid (ICS) persistence in pediatric patients using a single inhaler, containing both an inhaled corticosteroid (fluticasone propionate, FP) and an inhaled long-acting beta-agonist (salmeterol, SAL) (FSC), to patients receiving FP alone, FP + SAL from separate inhalers, or ICS + montelukast (MON)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T329","span":{"begin":0,"end":433},"obj":"Sentence"}],"text":"Medication compliance is recognized as a significant challenge in pediatrics.The purpose of this study was to compare inhaled corticosteroid (ICS) persistence in pediatric patients using a single inhaler, containing both an inhaled corticosteroid (fluticasone propionate, FP) and an inhaled long-acting beta-agonist (salmeterol, SAL) (FSC), to patients receiving FP alone, FP + SAL from separate inhalers, or ICS + montelukast (MON)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T4733","span":{"begin":103,"end":106},"obj":"Disease"},{"id":"T4734","span":{"begin":142,"end":145},"obj":"Disease"},{"id":"T4735","span":{"begin":409,"end":412},"obj":"Disease"}],"attributes":[{"id":"A4733","pred":"mondo_id","subj":"T4733","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"id":"A4734","pred":"mondo_id","subj":"T4734","obj":"http://purl.obolibrary.org/obo/MONDO_0016575"},{"id":"A4735","pred":"mondo_id","subj":"T4735","obj":"http://purl.obolibrary.org/obo/MONDO_0016575"}],"text":"Medication compliance is recognized as a significant challenge in pediatrics.The purpose of this study was to compare inhaled corticosteroid (ICS) persistence in pediatric patients using a single inhaler, containing both an inhaled corticosteroid (fluticasone propionate, FP) and an inhaled long-acting beta-agonist (salmeterol, SAL) (FSC), to patients receiving FP alone, FP + SAL from separate inhalers, or ICS + montelukast (MON)."}